OncoTherapy Science, Inc. (TYO:4564)

Market Cap	8.05B
Revenue (ttm)	750.00M
Net Income (ttm)	-815.00M
Shares Out	277.64M
EPS (ttm)	-3.12
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,905,800
Average Volume	8,789,405
Open	30.00
Previous Close	29.00
Day's Range	28.00 - 30.00
52-Week Range	21.00 - 64.00
Beta	0.06
RSI	53.83
Earnings Date	Aug 8, 2025

About OncoTherapy Science

OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-clinical stag...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 47
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4564

Financial Performance

In 2024, OncoTherapy Science's revenue was 750.00 million, an increase of 22.95% compared to the previous year's 610.00 million. Losses were -815.00 million, -36.72% less than in 2023.